Plus Therapeutics Says It Has Been Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda For Breast Cancer Treatment with Leptomeningeal Metastases
Portfolio Pulse from Benzinga Newsdesk
Plus Therapeutics has been granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda, a drug for breast cancer treatment with leptomeningeal metastases.
November 03, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Plus Therapeutics' FDA Orphan Drug Designation for its breast cancer treatment drug could potentially boost its stock in the short term.
The FDA Orphan Drug Designation is a significant milestone for Plus Therapeutics. This could potentially lead to increased investor confidence and a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100